Pomerantz LLP Files Class Action Against LifeMD for Securities Fraud.

A class-action lawsuit has been filed against LifeMD, Inc. (NASDAQ: LFMD) alleging securities fraud or other unlawful business practices. The lawsuit concerns investors who purchased LifeMD securities during the class period. Those interested in joining the class action must ask the court to appoint them as Lead Plaintiff by October 27, 2025. The complaint can be obtained at pomerantzlaw.com.

Investors of LifeMD, Inc. (NASDAQ: LFMD) are urged to take note of a significant development. A class-action lawsuit has been filed against the company, alleging securities fraud and other unlawful business practices. The lawsuit targets investors who purchased LifeMD securities during the specified class period. Those interested in joining the class action must ask the court to appoint them as Lead Plaintiff by October 27, 2025 [1].

The complaint, filed by Glancy Prongay & Murray LLP, alleges that LifeMD made materially false and misleading statements and failed to disclose material adverse facts about its business, operations, and prospects during the Class Period (May 7, 2025, to August 5, 2025) [1]. Specifically, the company is accused of overstating its competitive position and being reckless in raising its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment. These actions, the complaint argues, led to materially misleading statements about the company’s business, operations, and prospects.

On August 5, 2025, LifeMD announced that it was revising its full-year 2025 guidance due to temporary challenges facing its Rex MD business. This announcement resulted in a significant drop in the company’s stock price, falling $5.31 per share or 44.8% to close at $6.53 per share on August 6, 2025 [1].

Pomerantz LLP, a prominent law firm known for its work in corporate and securities litigation, is also investigating claims on behalf of LifeMD investors. Pomerantz LLP has advised investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, if they wish to join the class action [2].

Investors who believe they may have suffered losses due to these alleged practices are encouraged to contact Glancy Prongay & Murray LLP for more information. The firm can be reached at shareholders@glancylaw.com or by phone at 310-201-9150, toll-free at 888-773-9224. More details can be found on their website at www.glancylaw.com [1].

References:
[1] https://www.morningstar.com/news/business-wire/20250905627675/deadline-alert-lifemd-inc-lfmd-investors-who-lost-money-urged-to-contact-glancy-prongay-murray-llp-about-securities-fraud-lawsuit
[2] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-lifemd-inc-lfmd-ce7d59dbd88cf326